Evidence map›Paper›PMID 34094825›Full record

ReviewActa pharmaceutica Sinica. B2021

New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors.

Xu Hu, Yan Xiao, Jianan Sun, Bao Ji, Shanshan Luo, Bo Wu, Chao Zheng, Peng Wang, Fanxing Xu, Keguang Cheng and 2 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Inhibition of HJournal of vascular research · 2026
    Article
  4. Review
  5. Targeted HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Thio-ProTide strategy: A novel HActa pharmaceutica Sinica. B · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Xu HuKey Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yan XiaoSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jianan SunKey Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.
Bao JiKey Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shanshan LuoKey Laboratory of Cardiovascular and Cerebrovascular Medicine, Nanjing Medical University, Nanjing 211166, China.
Bo WuMolecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Charlestown, MA 02129, USA.
Chao ZhengPET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06520, USA.
Peng WangDepartment of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China.
Fanxing XuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Keguang ChengState Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources; School of Chemistry and Pharmacy, Guangxi Normal University, Guilin 541004, China.
Huiming HuaKey Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.
Dahong LiKey Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shenyang Pharmaceutical University · CNChina Pharmaceutical University · CNGuangxi Normal University · CNHarvard University · USNanjing Medical University · CNYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As one of the most lethal diseases, pancreatic cancer shows a dismal overall prognosis and high resistance to most treatment modalities. Furthermore, pancreatic cancer escapes early detection during the curable period because early symptoms rarely emerge and specific markers for this disease have not been found. Although combinations of new drugs, multimodal therapies, and adjuvants prolong survival, most patients still relapse after surgery and eventually die. Consequently, the search for more effective treatments for pancreatic cancer is highly relevant and justified. As a newly re-discovered mediator of gasotransmission, hydrogen sulfide (H

Indexed as

3-MST, 3-mercaptopyruvate sulfurtransferaseAMPK, adenosine 5′-monophosphate-activated protein kinaseAntitumor effectBCL-2, B-cell lymphoma-2BITC, benzyl isothiocyanateBRCA2, breast cancer 2CAT, cysteine aminotransferaseCBS, cystathionine-β-synthaseCDC25B, cell division cycle 25BCDK1, cyclin-dependent kinase 1Cell proliferationCHK2, checkpoint kinase 2CSE, cystathionine-γ-lyaseDATS, diallyl trisulfideDR4, death receptorEMT, epithelial–mesenchymal transitionERK1/2, extracellular signal-regulated kinaseERU, erucinFOXM1, forkhead box protein M1GLUTs, glucose transportersH2S, hydrogen sulfideHDAC, histone deacetylaseHEATR1, human HEAT repeat-containing protein 1HIF-1α, hypoxia inducible factorHydrogen sulfide donoriNOS, inducible nitric oxide synthaseITCs, isothiocyanatesJNK, c-Jun N-terminal kinaseKEAP1‒NRF2‒ARE, the recombinant protein 1-nuclear factor erythroid-2 related factor 2-antioxidant response elementKRAS, kirsten rat sarcoma viral oncogeneNF-κB, nuclear factor kappa BNO, nitric oxideOCT-4, octamer-binding transcription factor 4P16, multiple tumor suppressor 1Pancreatic cancerPARP, poly(ADP-ribose)-polymerasePDGFRα, platelet-derived growth factor receptorPEITC, phenethyl isothiocyanatePI3K/AKT, phosphoinositide 3-kinase/v-AKT murine thymoma viral oncogeneRASAL2, RAS protein activator like 2ROS, reactive oxygen speciesRPL10, human ribosomal protein L10SFN, sulforaphaneSHH, sonic hedgehogSignaling pathwaySMAD4, mothers against decapentaplegic homolog 4STAT-3, signal transducer and activator of transcription 3Sulfur-containing compoundTRAIL, The human tumor necrosis factor-related apoptosis-inducing ligandVEGF, vascular endothelial growth factorXIAP, X-linked inhibitor of apoptosis proteinZEB1, zinc finger E box-binding protein-1

Identifiers

PMID34094825
PMCPMC8144891
OpenAlexW3094736039

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.